What are the key changes in director compensation for HCA Healthcare?

HCA Healthcare has updated its Board of Directors compensation program for 2022-2023. This includes specific cash retainers for Board service, committee membership, and leadership roles (e.g., Committee Chairs, Board Chair). Additionally, a significant annual equity award of $190,000 in restricted stock units (RSUs) is now provided to non-management directors, which generally vest one year after the grant date.

How are HCA directors incentivized to hold company stock?

The new compensation program incorporates a stock ownership requirement, mandating that non-management directors acquire HCA common stock valued at five times their annual cash retainer for Board service within five years of their election. This, along with the annual RSUs that vest over time, aligns director interests with those of long-term shareholders.

What were the outcomes of the shareholder votes at the Annual Meeting?

Shareholders overwhelmingly re-elected all eleven director nominees and ratified the appointment of Ernst & Young LLP as the independent auditor. An advisory vote on executive compensation was also approved. However, shareholder proposals requesting increased disclosure on political spending and lobbying activities did not pass.

Can directors choose how they receive their compensation?

Yes, directors have some flexibility. They can elect to receive their annual retainer for Board service or for service as Chairman of the Board or independent presiding director in either cash or restricted share units. They also have the option to defer the receipt of shares from their annual equity awards.

HCA 8-K: Leadership Changes & Shareholder Matters

Summary

HCA Healthcare, Inc. (HCA) filed an 8-K report on April 25, 2022, detailing key governance and shareholder decisions from their Annual Meeting of Stockholders held on April 21, 2022. The primary focus of the filing is the approval of the 2022-2023 Board of Directors compensation program, which includes updated cash retainers and equity awards for non-management directors. This program aims to align director compensation with industry standards and incentivize long-term commitment through restricted share units and stock ownership requirements. The filing also provides the voting results from the Annual Meeting, confirming the election of all eleven director nominees with overwhelming support. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the upcoming fiscal year and approved an advisory resolution on executive compensation. Notably, two shareholder proposals concerning political spending and lobbying disclosure were not approved by a majority of the votes cast.

Key Highlights

1HCA's Board of Directors approved a new compensation program for non-management directors for 2022-2023, effective immediately.
2The new program includes a mix of cash retainers and equity awards, with annual retainers ranging from $15,000 for committee members to $100,000 for the Board Chair.
3Non-management directors will receive an annual equity award valued at $190,000, consisting of restricted share units that vest typically one year after the grant date.
4Directors have the option to receive cash retainers or board equity awards in the form of restricted share units, with further options for deferring share receipt.
5A stock ownership guideline requires non-management directors to acquire HCA common stock valued at five times their annual cash retainer within five years of election.
6All eleven director nominees were overwhelmingly elected to the Board for a one-year term.
7Ernst & Young LLP was ratified as HCA's independent auditor for the year ending December 31, 2022, with strong shareholder support.

HCA Healthcare, Inc. 8-K Report, Executive Changes (Apr 26, 2022)

Summary

Key Highlights

Frequently Asked Questions